Pharmacokinetics and Pharmacological/Bioactive Studies of Oridonin Derivatives in Anti-tumor Research

Yao Sang

doi:10.62051/cne0eh26

Authors

Yao Sang

DOI:

https://doi.org/10.62051/cne0eh26

Keywords:

oridonin derivatives; pharmacokinetics; anti-tumor; proliferation; migration and invasion; apoptosis.

Abstract

Objective: it to investigate the pharmacokinetics of oridonin derivatives and their effects on tumor cell proliferation (Pro), invasion (Inv), and apoptosis (Apo), aiming to provide a theoretical basis for cancer treatment. Materials and Methods: drug and statistics (DAS) software was utilized to analyze the average blood concentration-time data collected, determining pharmacokinetic parameters. Human breast cancer MCF-7 cells were used as experimental cells. Cells were rolled into three groups: Group A (GA, 0 μM), Group B (GB, 2 μM), and Group C (GC, 4 μM) treated with 15 μL of different concentrations of oridonin derivative CYD0618. Cell Pro and cytotoxicity were evaluated using the MTT assay, while Apo, Inv, migration (Mig), and protein expression changes were assessed using flow cytometry, Transwell assays, and Western blotting, respectively. Results: over time, the average blood drug concentration gradually declined, notably within 5 hours. Pharmacokinetic analysis revealed initial distribution half-life (t1/2α) of approximately 2.104 hours, elimination half-life (t1/2β) of 69.303 hours, area under the concentration-time curve (AUC) of 41.637 mg/h/L, clearance rate (CL) of 0.089 L/h/kg, and apparent volume of distribution (V) of 0.4 L/kg. GB and GC exhibited greatly lower cell counts than GA (P<0.05), with GC showing fewer cells relative to GB (P<0.05). The Mig of tumor cells was notably reduced in GB and GC versus GA (P<0.05), and GC showed fewer migrated cells than GB (P<0.05). Furthermore, Inv of tumor cells was markedly lower in GB and GC versus GA (P<0.05), with GC demonstrating fewer invasive cells than GB (P<0.05). Apo rates were greatly higher in GB and GC relative to GA (P<0.05), and GC had a higher Apo rate than GB (P<0.05). Additionally, STAT3 and p-STAT3 levels were substantially higher in GB and GC versus GA (P<0.05), with GB showing notably higher p-STAT3 expression than GC (P<0.05). Conclusion: oridonin derivatives can inhibit tumor cell Pro, Inv, and Mig by suppressing STAT3 phosphorylation and promoting tumor cell Apo.

Downloads

Download data is not yet available.

References

[1] Zhou F, Gao H, Shang L, Li J, Zhang M, Wang S, Li R, Ye L, Yang S. Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer. J Exp Clin Cancer Res. 2023 Jun 19;42(1):150. doi: 10.1186/s13046-023-02702-4. PMID: 37337284; PMCID: PMC10278272.

[2] Hwang TL, Chang CH. Oridonin enhances cytotoxic activity of natural killer cells against lung cancer. Int Immunopharmacol. 2023 Sep; 122:110669. doi: 10.1016/j.intimp.2023.110669. Epub 2023 Jul 20. PMID: 37480753.

[3] Zhang W, Shi L, Zhou W, Liu X, Xi Y, Wang X, Li Y, Xu X, Tang Y. Oridonin impedes breast cancer growth by blocking cells in S phase and inhibiting the PI3K/AKT/mTOR signaling pathway. Heliyon. 2023 Jul 11;9(7): e18046. doi: 10.1016/j.heliyon.2023.e18046. PMID: 37519735; PMCID: PMC10372243.

[4] Gao S, Tan H, Li D. Oridonin suppresses gastric cancer SGC-7901 cell proliferation by targeting the TNF-alpha/androgen receptor/TGF-beta signalling pathway axis. J Cell Mol Med. 2023 Sep;27(18):2661-2674. doi: 10.1111/jcmm.17841. Epub 2023 Jul 11. PMID: 37431884; PMCID: PMC10494293.

[5] Gao J, Li C, Wang X, Sun X, Zhang R, Chen C, Yu M, Liu Y, Zhu Y, Chen J. Oridonin attenuates lung inflammation and fibrosis in silicosis via covalent targeting iNOS. Biomed Pharmacother. 2022 Sep; 153: 113532. doi: 10.1016/j.biopha.2022.113532. Epub 2022 Aug 10. PMID: 36076611.

[6] Liu W, Wang X, Wang L, Mei Y, Yun Y, Yao X, Chen Q, Zhou J, Kou B. Oridonin represses epithelial-mesenchymal transition and angiogenesis of thyroid cancer via downregulating JAK2/STAT3 signaling. Int J Med Sci. 2022 May 27;19(6):965-974. doi: 10.7150/ijms.70733. PMID: 35813296; PMCID: PMC9254367.

[7] Cai M, Yao Y, Yin D, Zhu R, Fu T, Kong J, Wang K, Liu J, Yao A, Ruan Y, Shi W, Zhu Q, Ni J, Yin X. Enhanced lysosomal escape of cell penetrating peptide-functionalized metal-organic frameworks for co-delivery of survivin siRNA and oridonin. J Colloid Interface Sci. 2023 Sep 15; 646: 370-380. doi: 10.1016/j.jcis.2023.04.126. Epub 2023 Apr 28. PMID: 37207419.

[8] Wang Y, Wang M, Lin F, Zhang X, Zhao Y, Guo C, Wang J. Preparation, Characterization, and Evaluation of Liposomes Containing Oridonin from Rabdosia rubescens. Molecules. 2022 Jan 27;27(3):860. doi: 10.3390/molecules27030860. PMID: 35164121; PMCID: PMC8839758.

[9] Chen L, Li D, Guo X, Cheng C, Wei X. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling. Front Biosci (Landmark Ed). 2023 Sep 6;28(9):195. doi: 10.31083/j.fbl2809195. PMID: 37796705.

[10] Xu L, Jiang Y, Bi Y, Zheng S, Wu Y, Wu Y, Xu Y, Chen J. Suppression of PERK/eIF2α/CHOP pathway enhances oridonin-induced apoptosis by inhibiting autophagy in Small-Cell lung cancer cells. Biomed Pharmacother. 2024 Jun; 175: 116684. doi: 10.1016/j.biopha.2024.116684. Epub 2024 May 6. PMID: 38713951.

[11] Jin X, Xu J, Yang F, Chen J, Luo F, Xu B, Xu J. Oridonin Attenuates Thioacetamide-Induced Osteoclastogenesis Through MAPK/NF-κB Pathway and Thioacetamide-Inhibited Osteoblastogenesis Through BMP-2/RUNX2 Pathway. Calcif Tissue Int. 2023 Jun;112(6):704-715. doi: 10.1007/s00223-023-01080-5. Epub 2023 Apr 9. PMID: 37032340; PMCID: PMC10198936.

[12] Chen B, Liu X, Li Y, Shan T, Bai L, Li C, Wang Y. iRGD Tumor-Penetrating Peptide-Modified Nano-Delivery System Based on a Marine Sulfated Polysaccharide for Enhanced Anti-Tumor Efficiency Against Breast Cancer. Int J Nanomedicine. 2022 Feb 9; 17: 617-633. doi: 10.2147/IJN.S343902. PMID: 35173433; PMCID: PMC8842734.

[13] Yang H, Wang J, Khan S, Zhang Y, Zhu K, Zhou E, Gong M, Liu B, Kan Q, Zhang Q. Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells. Anticancer Drugs. 2022 Jan 1;33(1): e444-e452. doi: 10.1097/CAD.0000000000001237. PMID: 34520434; PMCID: PMC8670348.

[14] Zhang S, Vijayalakshmi A, Meng L. Oridonin attenuated human PC-3 cell activity by modulating the Wnt/β-catenin signaling. Adv Clin Exp Med. 2024 May;33(5):511-518. doi: 10.17219/acem/175519. PMID: 38269477.

[15] Wu G, Guo Y, Liu Y, Cai X, Deng T, Pei T, Huang L, Chen K, Pan X. Network-Based Method to Investigate the Promoted Cell Apoptosis Mechanisms of Oridonin in OSCC through the RNA-Transcriptome. J Immunol Res. 2023 Mar 16; 2023: 5293677. doi: 10.1155/2023/5293677. PMID: 36969496; PMCID: PMC10036191.

[16] Sun H, Nai J, Deng B, Zheng Z, Chen X, Zhang C, Sheng H, Zhu L. Angelica Sinensis Polysaccharide-Based Nanoparticles for Liver-Targeted Delivery of Oridonin. Molecules. 2024 Feb 5; 29(3): 731. doi: 10.3390/molecules29030731. PMID: 38338476; PMCID: PMC10856552.

[17] Wu Q, Gao X, Lin Y, Wu C, Zhang J, Chen M, Wen J, Wu Y, Tian K, Bao W, Sun P, Zhu A. Integrating Epigenetics, Proteomics, and Metabolomics to Reveal the Involvement of Wnt/β-Catenin Signaling Pathway in Oridonin-Induced Reproductive Toxicity. Toxics. 2024 May 7;12(5):339. doi: 10.3390/toxics12050339. PMID: 38787118; PMCID: PMC11126149.

[18] Zhou J, Li Y, Shi X, Hao S, Zhang F, Guo Z, Gao Y, Guo H, Liu L. Oridonin inhibits tumor angiogenesis and induces vessel normalization in experimental colon cancer. J Cancer. 2021 Apr 2; 12(11): 3257-3264. doi: 10.7150/jca.55929. PMID: 33976735; PMCID: PMC8100792.

[19] Liu X, Xu J, Zhou J, Shen Q. Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance. Genes Dis. 2020 Jul 5;8(4):448-462. doi: 10.1016/j.gendis.2020.06.010. PMID: 34179309; PMCID: PMC8209342.

[20] Kazantseva L, Becerra J, Santos-Ruiz L. Oridonin enhances antitumor effects of doxorubicin in human osteosarcoma cells. Pharmacol Rep. 2022 Feb;74(1):248-256. doi: 10.1007/s43440-021-00324-1. Epub 2021 Aug 24. PMID: 34427908; PMCID: PMC8786785.

[21] Hua X, Wu P, Gao GS, Ye XL. Combination of oridonin and TRAIL induces apoptosis in uveal melanoma cells by upregulating DR5. Int J Ophthalmol. 2021 Dec 18;14(12):1834-1842. doi: 10.18240/ijo.2021.12.05. PMID: 34926196; PMCID: PMC8640766.

[22] Abdullah NA, Md Hashim NF, Ammar A, Muhamad Zakuan N. An Insight into the Anti-Angiogenic and Anti-Metastatic Effects of Oridonin: Current Knowledge and Future Potential. Molecules. 2021 Feb 3;26(4):775. doi: 10.3390/molecules26040775. PMID: 33546106; PMCID: PMC7913218.

[23] Liu W, Huang G, Yang Y, Gao R, Zhang S, Kou B. Oridonin inhibits epithelial-mesenchymal transition of human nasopharyngeal carcinoma cells by negatively regulating AKT/STAT3 signaling pathway. Int J Med Sci. 2021 Jan 1;18(1):81-87. doi: 10.7150/ijms.48552. PMID: 33390776; PMCID: PMC7738957.

[24] Che X, Zhan J, Zhao F, Zhong Z, Chen M, Han R, Wang Y. Oridonin Promotes Apoptosis and Restrains the Viability and Migration of Bladder Cancer by Impeding TRPM7 Expression via the ERK and AKT Signaling Pathways. Biomed Res Int. 2021 Jul 5;2021:4340950. doi: 10.1155/2021/4340950. PMID: 34285910; PMCID: PMC8275389.

[25] Tan RZ, Yan Y, Yu Y, Diao H, Zhong X, Lin X, Liao YY, Wang L. Renoprotective Effect of Oridonin in a Mouse Model of Acute Kidney Injury via Suppression of Macrophage Involved Inflammation. Biol Pharm Bull. 2021;44(5):714-723. doi: 10.1248/bpb.b21-00071. PMID: 33952827.

[26] He S, Tian S, He X, Le X, Ning Y, Chen J, Chen H, Mu J, Xu K, Xiang Q, Wu Y, Chen J, Xiang T. Multiple targeted self-emulsifying compound RGO reveals obvious anti-tumor potential in hepatocellular carcinoma. Mol Ther Oncolytics. 2021 Aug 19;22:604-616. doi: 10.1016/j.omto.2021.08.008. PMID: 34589579; PMCID: PMC8449031.

[27] Yan SL, Huang CS, Mong MC, Yin MC. Oridonin Attenuates the Effects of Chronic Alcohol Consumption Inducing Oxidative, Glycative and Inflammatory Injury in the Mouse Liver. In Vivo. 2021 Jul-Aug;35(4):2141-2149. doi: 10.21873/invivo.12484. PMID: 34182490; PMCID: PMC8286538.

[28] Fan X, Wang T, Ji Z, Li Q, Shen H, Wang J. Synergistic combination therapy of lung cancer using lipid-layered cisplatin and oridonin co-encapsulated nanoparticles. Biomed Pharmacother. 2021 Sep;141:111830. doi: 10.1016/j.biopha.2021.111830. Epub 2021 Jun 17. PMID: 34146851.

[29] Liu Y, Song Z, Liu Y, Ma X, Wang W, Ke Y, Xu Y, Yu D, Liu H. Identification of ferroptosis as a novel mechanism for antitumor activity of natural product derivative a2 in gastric cancer. Acta Pharm Sin B. 2021 Jun;11(6):1513-1525. doi: 10.1016/j.apsb.2021.05.006. Epub 2021 May 13. PMID: 34221865; PMCID: PMC8245858.

[30] Tan Y, Zhou X, Gong Y, Gou K, Luo Y, Jia D, Dai L, Zhao Y, Sun Q. Biophysical and biochemical properties of PHGDH revealed by studies on PHGDH inhibitors. Cell Mol Life Sci. 2021 Dec 31;79(1):27. doi: 10.1007/s00018-021-04022-2. PMID: 34971423; PMCID: PMC11073335.